News & Events
Insight Genetics, in collaboration with partners at the British Columbia Cancer Agency, presented a poster at the American Society of Clinical Oncology’s 2014 Annual Meeting in Chicago. The poster highlighted a clinical diagnostic trial in Canada sponsored by Insight Genetics. The trial measures the accuracy of Insight Genetics’ ALK qPCR Assay in identifying oncogenic ALK expression in non-small cell lung cancer (NSCLC).
Insight Genetics CEO Eric Dahlhauser participated in a panel discussion at BIO-Europe’s 8th Annual Spring Conference, Europe's largest partnering conference serving the global biotechnology industry. The conference took place in Turin, Italy, from March 9-12, and gathered more than 2,000 participants from biotech and pharmaceutical companies, academic innovators, private investors and diagnostic companies from 42 countries.
Insight Genetics was featured as a case study in a special session hosted by the National Cancer Institute (NCI) and National Institutes of Health (NIH) at the American Association for Cancer Research (AACR) Annual Meeting in April 2014 in a session titled, “NCI SBIR Programs Support Technology Innovation for Cancer Detection and Treatment – with Insight Genetics.”
Insight Genetics and Vanderbilt-Ingram Cancer Center Partner to Improve Breast Cancer Diagnosis and Treatment
Insight Genetics, Inc. is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to enhance how researchers and oncologists classify and treat patients diagnosed with triple-negative breast cancer (TNBC). The molecular diagnostics company is working with VICC scientists to identify genetic markers that will help select the targeted therapeutics most effective for each individual TNBC patient.
Insight Genetics Awarded New National Cancer Institute Contract to Identify Resistance Mutations in Lung Cancer Patients
Insight Genetics, Inc. announced it has received a new $1.5 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). A continuation of a Phase I contract NCI awarded to Insight Genetics in 2011, the new contract will allow the company to continue its development of Insight ALK Resistance™, a diagnostic test that helps clinicians monitor their non-small cell lung cancer (NSCLC) patients for resistance to their prescribed cancer therapy.